Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, Zapotoczky H G
Universitätsklinik für Psychiatrie Wien, Austria.
Wien Klin Wochenschr. 1999 Jun 4;111(11):439-42.
In an 8-week double-blind placebo-controlled trial we studied the efficacy of fluoxetine (FLX) in 53 Austrian patients with obsessive compulsive disorder (OCD) diagnosed according to DSM-III-R. The dosage of FLX was fixed at either 20, 40, or 60 mg per day. Response was prospectively defined as an at least 25% reduction on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and an improvement on Clinical Global Impression (CGI) rating to at least "much improved" at the endpoint. Patients treated with at least 40 mg FLX per day showed significantly higher response rates than did those receiving either placebo or FLX 20 mg/day. Compulsions were more reduced than obsessions and we also observed a strong placebo effect which is largely attributable to an improvement in the Y-BOCS compulsion subscore.
在一项为期8周的双盲安慰剂对照试验中，我们研究了氟西汀（FLX）对53名根据DSM-III-R诊断为强迫症（OCD）的奥地利患者的疗效。FLX的剂量固定为每天20、40或60毫克。反应被前瞻性地定义为耶鲁-布朗强迫症量表（Y-BOCS）至少降低25%，且在终点时临床总体印象（CGI）评分改善至至少“明显改善”。每天接受至少40毫克FLX治疗的患者的反应率显著高于接受安慰剂或每天20毫克FLX治疗的患者。强迫症状比强迫观念减轻得更多，我们还观察到了很强的安慰剂效应，这在很大程度上归因于Y-BOCS强迫症状子评分的改善。
